Remyelination‐oriented clemastine treatment attenuates neuropathies of optic nerve and retina in glaucoma
Glia · 2024
DOI: 10.1002/glia.24543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glia, 2024. Verfasst von Kun Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Army Specialty Medical Center, Third Military Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Clemastine, Glaucoma, Retina, Mice, Inbred C57BL. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shenzhen Fundamental Research Program.
Abstract (Originalsprache)
As one of the top causes of blindness worldwide, glaucoma leads to diverse optic neuropathies such as degeneration of retinal ganglion cells (RGCs). It is widely accepted that the level of intraocular pressure (IOP) is a major risk factor in human glaucoma, and reduction of IOP level is the principally most well‐known method to prevent cell death of RGCs. However, clinical studies show that lowering IOP fails to prevent RGC degeneration in the progression of glaucoma. Thus, a comprehensive understanding of glaucoma pathological process is required for developing new therapeutic strategies. In this study, we provide functional and histological evidence showing that optic nerve defects occurred before retina damage in an ocular hypertension glaucoma mouse model, in which oligodendroglial lineage cells were responsible for the subsequent neuropathology. By treatment with clemastine, an Food and Drug Administration (FDA)‐approved first‐generation antihistamine medicine, we demonstrate that the optic nerve and retina damages were attenuated via promoting oligodendrocyte precursor cell (OPC) differentiation and enhancing remyelination. Taken together, our results reveal the timeline of the optic neuropathies in glaucoma and highlight the potential role of oligodendroglial lineage cells playing in its treatment. Clemastine may be used in future clinical applications for demyelination‐associated glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Army Specialty Medical Center, Third Military Medical University, Chongqing, China.
- Department of Histology and Embryology, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Neurobiology, Brain and Intelligence Research Key Laboratory of Chongqing Education Commission,…
- Research Centre, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Yixun Su, Lan Xiao, Jianqin Niu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shenzhen Fundamental Research Program
- Chongqing Natural Science Fund for Distinguished Young Scholars
Zitieren
APA
Liu, K., Yang, Y., Wu, Z., Sun, C., Su, Y., Huang, N., Wu, H., Yi, C., Ye, J., Xiao, L., & Niu, J. (2024). Remyelination‐oriented clemastine treatment attenuates neuropathies of optic nerve and retina in glaucoma. Glia. https://doi.org/10.1002/glia.24543
Vancouver
Liu K, Yang Y, Wu Z, Sun C, Su Y, Huang N, et al. Remyelination‐oriented clemastine treatment attenuates neuropathies of optic nerve and retina in glaucoma. Glia. 2024. doi:10.1002/glia.24543
BibTeX
@article{Liu2024,
author = {Liu, Kun and Yang, Yujian and Wu, Zhonghao and Sun, Chunhui and Su, Yixun and Huang, Nanxin and Wu, Haoqian and Yi, Chenju and Ye, Jian and Xiao, Lan and Niu, Jianqin},
title = {Remyelination‐oriented clemastine treatment attenuates neuropathies of optic nerve and retina in glaucoma},
journal = {Glia},
year = {2024},
doi = {10.1002/glia.24543}
}
EUVIMED